OptimizeRx
Market Cap
US$138.2m
Last Updated
2019/12/14 00:21 UTC
Data Sources
Company Financials +
Executive Summary
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Share Price & News
How has OptimizeRx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OPRX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.9%
OPRX
-1.1%
US Healthcare Services
0.6%
US Market
1 Year Return
-18.4%
OPRX
26.5%
US Healthcare Services
20.8%
US Market
Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned 26.5% over the past year.
Return vs Market: OPRX underperformed the US Market which returned 20.8% over the past year.
Shareholder returns
| OPRX | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.9% | -1.1% | 0.6% |
| 30 Day | 1.0% | 1.8% | 2.5% |
| 90 Day | -37.7% | 2.2% | 4.9% |
| 1 Year | -18.4%-18.4% | 26.7%26.5% | 23.5%20.8% |
| 3 Year | 311.4%311.4% | 89.2%88.5% | 46.5%37.0% |
| 5 Year | 242.1%242.1% | 64.4%62.9% | 64.6%46.5% |
Price Volatility Vs. Market
How volatile is OptimizeRx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Have Insiders Been Selling OptimizeRx Corporation (NASDAQ:OPRX) Shares This Year?1 month ago | Simply Wall St
OptimizeRx Corporation Just Reported And Analysts Have Been Cutting Their Estimates1 month ago | Simply Wall St
Should You Worry About OptimizeRx Corporation's (NASDAQ:OPRX) CEO Salary Level?Valuation
Is OptimizeRx undervalued compared to its fair value and its price relative to the market?
3.36x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: OPRX ($9.75) is trading above our estimate of fair value ($8.09)
Significantly Below Fair Value: OPRX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OPRX is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: OPRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OPRX is good value based on its PB Ratio (3.4x) compared to the US Healthcare Services industry average (3.9x).
Next Steps
Future Growth
How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
128.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: OPRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OPRX's is expected to become profitable in the next 3 years.
Revenue vs Market: OPRX's revenue (29.8% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: OPRX's revenue (29.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OptimizeRx performed over the past 5 years?
8.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPRX is currently unprofitable.
Growing Profit Margin: OPRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OPRX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-0.2%).
Return on Equity
High ROE: OPRX has a negative Return on Equity (-3.08%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is OptimizeRx's financial position?
Financial Position Analysis
Short Term Liabilities: OPRX's short term assets ($37.9M) exceed its short term liabilities ($5.4M).
Long Term Liabilities: OPRX's short term assets ($37.9M) exceed its long term liabilities ($2.0M).
Debt to Equity History and Analysis
Debt Level: OPRX is debt free.
Reducing Debt: OPRX had no debt 5 years ago.
Balance Sheet
Inventory Level: OPRX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if OPRX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OPRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is OptimizeRx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of OptimizeRx's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Will Febbo (50yo)
3.8yrs
Tenure
US$923,138
Compensation
Mr. William J. Febbo, also known as Will, has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 2016. Mr. Febbo is a Founder of Plexuus, an early stage payment processing ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD923.14K) is above average for companies of similar size in the US market ($USD526.35K).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.4yrs
Average Tenure
54yo
Average Age
Experienced Management: OPRX's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
2.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: OPRX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: OPRX insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 600 |
| Max Price | US$9.62 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman |
| Shares | 5,000 |
| Max Price | US$9.80 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 5,000 |
| Max Price | US$9.50 |
| Entity | Individual |
| Shares | 200,400 |
| Max Price | US$15.75 |
| Entity | Individual |
| Shares | 6,100 |
| Max Price | US$16.23 |
| Entity | Company |
| Shares | 5,310 |
| Max Price | US$16.05 |
| Entity | Company |
| Shares | 6,577 |
| Max Price | US$14.85 |
| Entity | Company |
| Shares | 42,874 |
| Max Price | US$13.63 |
| Entity | Company |
| Shares | 82,126 |
| Max Price | US$13.76 |
| Entity | Company |
| Shares | 21,397 |
| Max Price | US$15.15 |
| Entity | Individual |
| Role | President President |
| Shares | 1,015 |
| Max Price | US$9.85 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Director |
| Shares | 2,000 |
| Max Price | US$9.94 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.
Management Team
Will Febbo (50yo)
CEO & Director
- Tenure: 3.8yrs
- Compensation: US$923.14k
Doug Baker (62yo)
Chief Financial Officer
- Tenure: 5.6yrs
- Compensation: US$425.70k
Miriam Paramore (56yo)
President
- Tenure: 2.3yrs
- Compensation: US$445.28k
Terry Hamilton (54yo)
Senior Vice President of Sales
- Tenure: 3.9yrs
- Compensation: US$511.63k
James Brooks (50yo)
Consultant
- Tenure: 2.9yrs
- Compensation: US$420.99k
Steve Silvestro
Chief Commercial Officer
- Tenure: 0.7yrs
Board Members
Pat Spangler (63yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$105.78k
Will Febbo (50yo)
CEO & Director
- Tenure: 3.8yrs
- Compensation: US$923.14k
Gus Halas (68yo)
Independent Chairman
- Tenure: 2.5yrs
- Compensation: US$130.90k
Lynn Vos (63yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$103.15k
Jay Pinney (62yo)
Head of Medical Advisory Board
- Tenure: 1.8yrs
- Compensation: US$112.91k
Jim Lang (54yo)
Independent Director
- Tenure: 2.9yrs
- Compensation: US$120.28k
Company Information
OptimizeRx Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: OptimizeRx Corporation
- Ticker: OPRX
- Exchange: NasdaqCM
- Founded:
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$138.195m
- Shares outstanding: 14.17m
- Website: https://www.optimizerx.com
Number of Employees
Location
- OptimizeRx Corporation
- 400 Water Street
- Suite 200
- Rochester
- Michigan
- 48307
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OPRX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Jun 2005 |
Biography
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to med ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/14 00:21 |
| End of Day Share Price | 2019/12/13 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.